1. Home
  2. WTO vs DRMA Comparison

WTO vs DRMA Comparison

Compare WTO & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

WTO

UTime Limited

HOLD

Current Price

$1.13

Market Cap

2.4M

Sector

Technology

ML Signal

HOLD

Logo Dermata Therapeutics Inc.

DRMA

Dermata Therapeutics Inc.

HOLD

Current Price

$2.96

Market Cap

2.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WTO
DRMA
Founded
2008
2014
Country
China
United States
Employees
N/A
N/A
Industry
Consumer Electronics/Appliances
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4M
2.1M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
WTO
DRMA
Price
$1.13
$2.96
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
1.6M
95.9K
Earning Date
12-23-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$34,589,265.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
54.01
N/A
52 Week Low
$1.04
$2.34
52 Week High
$440.00
$23.70

Technical Indicators

Market Signals
Indicator
WTO
DRMA
Relative Strength Index (RSI) 61.50 43.92
Support Level $1.09 $2.66
Resistance Level $1.25 $3.16
Average True Range (ATR) 0.16 0.29
MACD 0.02 0.05
Stochastic Oscillator 58.18 64.02

Price Performance

Historical Comparison
WTO
DRMA

About WTO UTime Limited

UTime Ltd is engaged in the design, development, production, sales and brand operation of mobile phones, accessories and related consumer electronics. It also provides Electronics Manufacturing Services (EMS), including Original Equipment Manufacturer (OEM) and Original Design Manufacturer (ODM) services, for renowned brands. The company operates in China and its products are sold globally, including Mexico, Brazil, the United States, and other emerging markets in South Asia and Africa as well as Europe. It has two in-house brands, UTime, known as its middle-to-high end label and targets middle class consumers from emerging markets; as its low- to mid-end brand, is positioned to the grassroots consumers and price-sensitive consumers in emerging markets.

About DRMA Dermata Therapeutics Inc.

Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.

Share on Social Networks: